Details of Disease

General Information of Disease (ID: DISNHN2M)

• Disease Name: B-cell chronic lymphocytic leukaemia
• Disease Class: 2A82: Mature B-cell leukaemia
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISNHN2M: B-cell chronic lymphocytic leukaemia
• ICD Code:
  ICD-11: ICD-11: 2A82.00
  ICD-9: ICD-9: 204.1
  Expand ICD-11: '2A82.00
  Expand ICD-9: 204.1
• Disease Identifiers:
  MONDO ID: MONDO_0003864
  UMLS CUI: C1302547
  MedGen ID: 224906

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 12 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MOR-208	DMDQOWT	Phase 2/3	Antibody	[1]
CART-19	DMHQKN6	Phase 2	CAR T Cell Therapy	[2]
CD19 CAR T cells	DMEK580	Phase 2	CAR T Cell Therapy	[3]
CD20 CAR T cells	DMQGI8R	Phase 2	CAR T Cell Therapy	[3]
MT-3724	DMCNL7Z	Phase 2	Recombinant?protein	[1]
Anti-CD19 CAR-T	DM04HNB	Phase 1/2	CAR T Cell Therapy	[4]
Anti-CD19 CAR-T cells	DMSFEOC	Phase 1/2	CAR T Cell Therapy	[5]
Anti-CD19-CAR vector-transduced T cells	DMQXU4C	Phase 1/2	CAR T Cell Therapy	[6]
Anti-CD19/22-CAR vector-transduced T cells	DMMUSHR	Phase 1/2	CAR T Cell Therapy	[7]
Anti-CD20-CAR vector-transduced autologous T cells	DMCDUJY	Phase 1/2	CAR T Cell Therapy	[8]
BMS-936564	DMS4H1J	Phase 1	NA	[9]
Anti-CD19/20-CAR vector-transduced T cells	DM3M9OY	Clinical trial	CAR T Cell Therapy	[10]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
• [3] ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
• [4] ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
• [5] ClinicalTrials.gov (NCT02782351) Humanized CAR-T Therapy for Treatment of B Cell Malignancy
• [6] ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
• [7] ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
• [8] ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
• [9] ClinicalTrials.gov (NCT02305563) Phase 1 Study of BMS-936564. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20